Bon Natural Life Limited (NASDAQ:BON) announced on November 20, 2026, that its subsidiary Xi'an App-Chem Bio(Tech) Co., Ltd. and China Oat Group Co., Ltd. have established the BON Natural Ingredients and Biomanufacturing Joint Laboratory to develop AI-driven biomanufacturing technologies for oat-derived natural ingredients.
Key Highlights
- New joint laboratory: The BON Natural Ingredients and Biomanufacturing Joint Laboratory was announced by App-Chem and China Oat Group at a symposium themed "Advancing the High-Quality Development of China's Health Industry."
- Technology focus: The Joint Lab will develop an AI-driven technological platform for biomanufacturing of natural ingredients, with synthetic biology as its technological foundation.
- Target compounds: Primary research targets include oat-derived bioactive compounds such as beta-glucan and avenanthramides (AVAs), which the filing describes as having cardiovascular protection, blood glucose regulation, antioxidant, and anti-inflammatory properties.
- Standards development: The Joint Lab will conduct systematic testing and validation of ingredient purity, safety, and elemental and isotopic profiles as a dedicated area of focus.
- China Oat Group's patent portfolio: According to the filing, China Oat Group holds more than ten invention patents in China, along with multiple patents in the United States, Europe, Canada, Australia, and other markets.
- Company vision: BON described its stated goal as becoming an "AI-driven pioneer in digital nutrition," according to the press release.
App-Chem and China Oat Group Establish Biomanufacturing Joint Lab
According to the filing, BON's subsidiary Xi'an App-Chem Bio(Tech) Co., Ltd. recently convened a symposium with China Oat Group Co., Ltd. in Xi'an, China, at which the two parties announced the formation of the BON Natural Ingredients and Biomanufacturing Joint Laboratory. The Joint Lab is described as intended to build "an integrated innovation framework spanning the entire value chain, from fundamental research and pilot-scale development to standard-setting and industrial commercialization."
The filing states that oat-derived ingredients face supply and cost challenges, noting that "limited availability of natural raw materials and high sourcing costs have constrained the broader commercial application and market expansion of oat-derived products." BON and China Oat Group disclosed that the Joint Lab aims to address challenges related to supply availability, supply stability, and high production costs through biomanufacturing technologies. The filing also notes that China Oat Group was among the first companies to achieve large-scale, standardized deep processing of oats, with related technologies receiving what the filing describes as "authoritative certifications in Europe and the United States."
On standards, the filing states that the Joint Lab will make standards development a dedicated focus, evaluating ingredient purity, safety, and elemental and isotopic profiles. BON Chairman Yongwei Hu was quoted in the filing as stating that the collaboration "marks a pivotal step" in the company's efforts to expand into the global biomanufacturing market. The press release notes that statements about the Joint Lab's expected outcomes are forward-looking and subject to the risks and uncertainties discussed in the company's periodic reports filed with the Securities and Exchange Commission.
What Was Disclosed
Bon Natural Life Limited disclosed the formation of a joint laboratory with China Oat Group, focused on AI-driven biomanufacturing of oat-derived natural ingredients. The announcement covers the lab's research scope, standards development mandate, and the patent holdings of China Oat Group.




Please wait processing your request...